Elite Journal of Haematology. Volume 2 issue 3(2024), Pp. 58-66
https://epjournals.com/journals/EJH

Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review

[*]Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda.

[2]School of Nursing Science, Kampala International University, Uganda.

[*]Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Sickle cell anemia (SCA) is a hereditary hemoglobinopathy characterized by the presence of abnormal hemoglobin S (HbS), leading to the polymerization of red blood cells and the hallmark sickling phenomenon. While the mechanical fragility and vaso-occlusive properties of sickled erythrocytes have long been recognized as central to the pathophysiology of SCA, emerging evidence suggests a pivotal role for oxidative damage in driving vascular complications. This review delves into the mechanisms underlying oxidative damage in SCA, its contribution to endothelial dysfunction and vascular complications, and the potential therapeutic implications of antioxidant strategies. The intricate interplay between intravascular hemolysis, ischemia-reperfusion injury, inflammation, and altered redox signaling pathways contributes to oxidative damage in SCA. The release of free heme and iron from hemolyzed erythrocytes promotes the generation of reactive oxygen species (ROS), exacerbating oxidative stress and endothelial dysfunction. Activated leukocytes and platelets further perpetuate ROS production and inflammation, amplifying tissue injury and vaso-occlusive events. Endothelial dysfunction, characterized by impaired nitric oxide bioavailability, increased adhesion molecule expression, and a prothrombotic phenotype, is a hallmark of vascular complications in SCA. Oxidative stress-induced alterations in endothelial function contribute to vaso-occlusive crises, microvascular thrombosis, and tissue ischemia, culminating in acute and chronic organ damage. Additionally, oxidative stress promotes vascular remodeling and fibrosis, further exacerbating the progression of vascular complications in SCA.

Citation: Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. *Elite Journal of Haematology, 2024; 2(3):* 58-66

Keywords: *Sickle Cell Anemia, Oxidative Damage, Vascular Complications, Reactive Oxygen Species, Endothelial Dysfunction, Antioxidant Therapy*

Introduction

Sickle cell anemia (SCA) stands as one of the most prevalent and debilitating inherited hemoglobinopathies globally, characterized by the presence of abnormal hemoglobin S (HbS). The hallmark sickling phenomenon, where red blood cells adopt a rigid, crescent shape under conditions of hypoxia or stress, leads to vaso-occlusive events, tissue ischemia, and chronic organ damage. While the mechanical properties of sickled erythrocytes have long been recognized as central to the pathophysiology of SCA, growing evidence suggests that oxidative damage plays a critical role in driving vascular complications, further complicating the clinical course of the disease. The interplay of multiple factors contributes to oxidative damage in SCA, including intravascular hemolysis, ischemia-reperfusion injury, inflammation, and altered redox signaling pathways. Hemolyzed erythrocytes release free heme and iron, triggering the generation of reactive oxygen species (ROS) and exacerbating oxidative stress. Additionally, activated leukocytes and platelets contribute to ROS production and inflammation, amplifying tissue injury and promoting vaso-occlusive events.[1-23]

Endothelial dysfunction represents a hallmark feature of vascular complications in SCA, characterized by impaired nitric oxide bioavailability, increased expression of adhesion molecules, and a prothrombotic phenotype. Oxidative stress-induced alterations in endothelial function contribute to microvascular thrombosis, vaso-occlusive crises, and tissue ischemia, underpinning the development of acute and chronic organ damage. Moreover, oxidative damage promotes vascular remodeling and fibrosis, further exacerbating the progression of vascular complications in individuals with SCA. Therapeutic strategies targeting oxidative damage hold promise for mitigating vascular complications and improving outcomes in SCA. Antioxidant therapies, such as hydroxyurea, N-acetylcysteine, and vitamin E, have demonstrated efficacy in reducing oxidative stress, enhancing nitric oxide bioavailability, and ameliorating endothelial dysfunction in experimental and clinical studies. However, the optimal timing, dosing, and combination therapies for antioxidant interventions in SCA remain areas of ongoing research and investigation.[24-38]

Mechanisms of Oxidative Damage

The pathophysiology of oxidative damage in sickle cell anemia (SCA) encompasses a multifaceted interplay of cellular and molecular mechanisms, involving intravascular hemolysis, ischemia-reperfusion injury, inflammation, and dysregulated redox signaling pathways. These mechanisms contribute to the generation of reactive oxygen species (ROS), ultimately leading to cellular injury, endothelial dysfunction, and vascular complications characteristic of SCA. Hemolytic anemia is a hallmark feature of SCA, driven by the increased fragility and decreased lifespan of sickled

erythrocytes. Hemolysis releases free hemoglobin into the circulation, where it undergoes oxidation to form methemoglobin and release heme. The subsequent breakdown of heme releases free iron, which catalyzes the Fenton reaction, generating highly reactive hydroxyl radicals and exacerbating oxidative stress. Additionally, cell-free hemoglobin and heme directly contribute to endothelial injury and dysfunction, further amplifying oxidative damage.[39-45]

Vaso-occlusive events in SCA result in tissue ischemia, followed by reperfusion upon restoration of blood flow.[46] Ischemia-reperfusion injury triggers the production of ROS through various pathways, including mitochondrial dysfunction, xanthine oxidase activation, and neutrophil and platelet activation. The sudden reintroduction of oxygen during reperfusion leads to the generation of superoxide radicals, hydrogen peroxide, and other ROS, which contribute to endothelial damage, microvascular thrombosis, and tissue injury. Chronic inflammation is a hallmark feature of SCA, characterized by elevated levels of proinflammatory cytokines and activated leukocytes in the circulation. Inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β) stimulate the production of ROS by activating nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in leukocytes and endothelial cells. Additionally, activated leukocytes release myeloperoxidase and other enzymes that further contribute to oxidative stress and tissue damage. Dysregulated redox signaling pathways play a pivotal role in oxidative damage in SCA. The imbalance between ROS production and antioxidant defense mechanisms disrupts redox homeostasis, leading to oxidative stress and cellular injury. Moreover, altered redox signaling pathways contribute to endothelial dysfunction, increased adhesion molecule expression, and enhanced leukocyte-endothelial interactions, further promoting vaso-occlusive events and tissue damage.

Endothelial Dysfunction and Vascular Complications

Endothelial dysfunction represents a pivotal aspect of vascular pathology in sickle cell anemia (SCA), contributing to the development of vaso-occlusive events, microvascular thrombosis, and tissue ischemia.[47] The complex interplay between oxidative damage, inflammation, and altered redox signaling pathways disrupts endothelial homeostasis, leading to impaired nitric oxide (NO) bioavailability, increased adhesion molecule expression, and a prothrombotic endothelial phenotype. Nitric oxide (NO) is a key regulator of vascular tone, platelet adhesion, and leukocyte-endothelial interactions, exerting vasodilatory, anti-inflammatory, and antithrombotic effects. In SCA, oxidative stress and decreased NO bioavailability contribute to endothelial dysfunction, resulting in vasoconstriction, enhanced platelet activation, and leukocyte recruitment. The impaired NO-mediated vasodilation further exacerbates tissue ischemia and promotes vaso-occlusive events in affected individuals.

Endothelial activation in SCA is characterized by increased expression of adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin.[48] Upregulation of adhesion molecules promotes the adhesion and

transendothelial migration of leukocytes and platelets, facilitating their recruitment to sites of vascular injury and promoting microvascular occlusion. This enhanced adhesive interaction between circulating cells and the endothelium contributes to the pathogenesis of vaso-occlusive crises and tissue ischemia in SCA. Endothelial dysfunction in SCA is associated with a prothrombotic endothelial phenotype characterized by increased tissue factor expression, reduced thrombomodulin activity, and impaired fibrinolysis. Tissue factor, a key initiator of the coagulation cascade, promotes thrombus formation and microvascular thrombosis in SCA. Moreover, decreased thrombomodulin activity and impaired fibrinolysis exacerbate thrombus stability and contribute to the persistence of vascular occlusion, further compromising tissue perfusion and promoting organ damage. Endothelial dysfunction-driven microvascular thrombosis represents a hallmark feature of SCA, leading to tissue ischemia and organ damage. The occlusion of small blood vessels by sickled erythrocytes, leukocytes, and platelets impairs blood flow and oxygen delivery to affected tissues, resulting in ischemic injury and infarction. The cumulative effect of recurrent vaso-occlusive events and tissue ischemia contributes to the development of chronic organ damage and systemic complications in individuals with SCA.

Therapeutic Implications

Addressing endothelial dysfunction and oxidative damage holds significant therapeutic promise in managing vascular complications associated with sickle cell anemia (SCA).[49] A multifaceted approach targeting oxidative stress, inflammation, and endothelial dysfunction is essential for improving vascular outcomes and reducing the burden of complications in individuals with SCA. Hydroxyurea, a disease-modifying agent, is a cornerstone of therapy in SCA due to its ability to increase fetal hemoglobin levels, reduce hemolysis, and mitigate oxidative stress. By inducing the production of fetal hemoglobin, hydroxyurea reduces the proportion of sickled erythrocytes, diminishes intravascular hemolysis, and alleviates oxidative damage. Moreover, hydroxyurea enhances nitric oxide bioavailability, improves endothelial function, and reduces the frequency of vaso-occlusive crises and acute complications in individuals with SCA. Antioxidant supplementation represents a promising therapeutic strategy for mitigating oxidative damage and improving vascular outcomes in SCA. N-acetylcysteine (NAC), vitamin E, and other antioxidants have been investigated for their ability to scavenge reactive oxygen species (ROS), restore redox balance, and protect against endothelial dysfunction. Clinical trials evaluating antioxidant supplementation have shown mixed results, highlighting the need for further research to determine the optimal dosing, duration, and efficacy of antioxidant therapies in SCA. L-arginine, the precursor of nitric oxide (NO), has been proposed as a therapeutic agent for improving endothelial function and increasing NO bioavailability in individuals with SCA. By replenishing NO levels, L-arginine promotes vasodilation, inhibits platelet activation, and attenuates vaso-occlusive events. Clinical studies investigating the effects of L-arginine supplementation in SCA have yielded conflicting results, with some demonstrating improvements in endothelial function and others showing no significant benefits. Further research is needed to elucidate the therapeutic potential of L-arginine supplementation in SCA.

Citation: Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. *Elite Journal of Haematology, 2024; 2(3):* 58-66

Targeting inflammation represents another potential therapeutic strategy for managing vascular complications in SCA.[50] Anti-inflammatory agents, such as corticosteroids, anti-TNF agents, and interleukin inhibitors, have been explored for their ability to suppress inflammatory cytokine production, reduce leukocyte activation, and attenuate endothelial dysfunction. However, the use of anti-inflammatory therapies in SCA remains controversial, with concerns regarding potential adverse effects and long-term safety. Emerging therapies targeting endothelial cell function and regeneration hold promise for improving vascular outcomes in SCA. Endothelial progenitor cell (EPC) transplantation, endothelial cell-targeted gene therapy, and endothelial cell-derived extracellular vesicles are being investigated for their potential to repair damaged endothelium, restore vascular homeostasis, and promote tissue regeneration in individuals with SCA. While still in the experimental stages, these innovative therapies represent exciting avenues for future research and therapeutic development in SCA.

Conclusion

The management of vascular complications in sickle cell anemia (SCA) presents a complex and multifaceted challenge, with endothelial dysfunction and oxidative damage playing central roles in disease pathogenesis. Endothelial dysfunction, characterized by impaired nitric oxide bioavailability, increased adhesion molecule expression, and a prothrombotic endothelial phenotype, contributes to vaso-occlusive events, microvascular thrombosis, and tissue ischemia. Oxidative damage, driven by intravascular hemolysis, ischemia-reperfusion injury, inflammation, and dysregulated redox signaling pathways, further exacerbates endothelial dysfunction and promotes vascular injury in SCA. Therapeutic interventions targeting endothelial dysfunction and oxidative damage hold promise for improving vascular outcomes and reducing the burden of complications in individuals with SCA. Hydroxyurea therapy, antioxidant supplementation, L-arginine supplementation, and anti-inflammatory agents have shown efficacy in mitigating oxidative stress, restoring endothelial function, and reducing the frequency of vaso-occlusive events in clinical studies. Additionally, emerging therapies targeting endothelial cell function and regeneration represent promising avenues for future research and therapeutic development in SCA.

References

1. Williams TN, Thein SL. Sickle cell anemia and its phenotypes. Annual review of genomics and human genetics. 2018; 19:113-147.
2. Pecker LH, Little J. Clinical manifestations of sickle cell disease across the lifespan. Sickle cell disease and hematopoietic stem cell transplantation. 2018:3-9.
3. Wang WC. Sickle cell anemia. Greer JP, Foerster J, Lukens JN, Rogers GM, Paraskevas F, Glader BE. Wintrobe's Clinical Hematology, 11th edition. Philadelphia, Pa, Lippincott Williams & Wilkins. 2004.
4. Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, Wang WC, Hoppe C, Hagar W, Darbari DS, Malik P. Beyond the definitions of the phenotypic

Citation: Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. *Elite Journal of Haematology, 2024; 2(3):* 58-66

complications of sickle cell disease: an update on management. The Scientific World Journal. 2012 Oct;2012.
5. Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, Wang WC, Hoppe C, Hagar W, Darbari DS, Malik P. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. The Scientific World Journal. 2012.
6. Alapan Y, Fraiwan A, Kucukal E, Hasan MN, Ung R, Kim M, Odame I, Little JA, Gurkan UA. Emerging point-of-care technologies for sickle cell disease screening and monitoring. Expert review of medical devices. 2016;13(12):1073-1093.
7. Efobi CC, Nri-Ezedi CA, Madu CS, Ikediashi CC, Ejiofor O, Ofiaeli CI. Neutrophil-Lymphocyte, Platelet-Neutrophil, and PlateletLymphocyte Ratios as Indicators of Sickle Cell Anaemia Severity. Ethiopian Journal of Health Sciences. 2023;33(5):821-830.
8. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
9. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
10. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
11. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
12. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023 Sep 11;6(4):12-17.
13. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
14. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-8.
15. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-0487.
16. Obeagu EI, Obeagu GU, Igwe MC, Alum EU, Ugwu OP. Men's Essential roles in the Management of Sickle Cell Anemia. **NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 4(2):20-29**. https://doi.org/10.59298/NIJSES/2023/10.3.1111
17. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
18. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.

Citation: Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. *Elite Journal of Haematology, 2024; 2(3):* 58-66

19. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
20. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine. 2023;102(48):e36462.
21. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
22. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
23. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU. Anaemia in children under five years: African perspectives. Int. J. Curr. Res. Biol. Med. 2023;1:1-7.
24. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
25. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
26. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
27. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.
28. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
29. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
30. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
31. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
32. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-5.
33. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
34. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.

Citation: Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. *Elite Journal of Haematology, 2024; 2(3):* 58-66

35. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
36. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO. Sickle Cell Anaemia: Current Burden in Africa. International Journal of Innovative and Applied Research. 2023;11(2):12-14.
37. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10; 6 (2): 10-13.
38. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
39. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
40. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-143.
41. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
42. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
43. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
44. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
45. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
46. Hebbel RP, Belcher JD, Vercellotti GM. The multifaceted role of ischemia/reperfusion in sickle cell anemia. The Journal of Clinical Investigation. 2020;130(3):1062-1072.
47. Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annual review of pathology: mechanisms of disease. 2019; 14:263-292.
48. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clinical rheumatology. 2005:111-116.

Citation: Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. *Elite Journal of Haematology, 2024; 2(3):* 58-66

49. Ansari J, Moufarrej YE, Pawlinski R, Gavins FN. Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease. Expert review of hematology. 2018;11(1):45-55.
50. Sreejit G, Johnson J, Jaggers RM, Dahdah A, Murphy AJ, Hanssen NM, Nagareddy PR. Neutrophils in cardiovascular disease: warmongers, peacemakers, or both? Cardiovascular research. 2022;118(12):2596-2609.

Citation: Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. *Elite Journal of Haematology, 2024; 2(3):* 58-66